Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Stage: Development Stage Company
Operations: The Company is a nano-biopharmaceutical firm focused on discovering and developing therapeutics for viral infections (HIV, Hepatitis, Influenza, Rabies, Ebola, etc.). It holds an exclusive perpetual license from TheraCour Pharma, Inc. for its core technology. The Company has generated no revenue to date and relies on financing to fund research and development.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 | Cumulative (Inception to Mar 31, 2008) |
|---|---|---|---|
| Revenues | $0 | $0 | $0 |
| Net Loss | $(790,887) | $(1,745,585) | $(8,214,985) |
| Operating Expenses | $805,318 | $1,793,155 | $7,537,920 |
| Cash and Cash Equivalents (Ending) | $1,210,836 | ||
| Total Assets | $1,889,556 | ||
| Total Liabilities | $513,217 | ||
| Shareholders' Equity | $1,376,339 | ||
| Shares Outstanding | 119,240,835 |
Cash Flow (Nine Months Ended Mar 31, 2008):
- Net cash used in operating activities: $(2,216,802)
- Net cash used in investing activities: $(40,179)
- Net cash provided by financing activities: $2,500,020 (primarily from private placements of common stock)
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss for the three months ended March 31, 2008, was $(790,887), a decrease from $(918,119) in the same period of 2007. The nine-month net loss decreased to $(1,745,585) from $(2,347,625) in the prior year.
- Expense Reduction: Total operating expenses decreased by approximately $123,000 for the three-month period and $515,000 for the nine-month period compared to the prior year. This was partially due to a refund credit for research and development costs of $166,050 recognized in the nine-month period.
- Liquidity Improvement: Cash and cash equivalents increased from $967,797 at June 30, 2007, to $1,210,836 at March 31, 2008, driven by $2.5 million in proceeds from the issuance of common stock.
- Liabilities: Total current liabilities decreased from $849,883 to $513,217, largely due to a reduction in accrued payroll to officers and related parties.
Outlook, Risks, and Management Commentary
Liquidity and Capital Resources
Management states that the current cash balance of $1,210,836 is sufficient to fund operations through August 31, 2008. However, the Company estimates it requires in excess of $5,000,000 to fund operations, capital costs, and staffing for the next twelve months. There is substantial doubt about the Company's ability to continue as a going concern without additional financing.
Operational Milestones
- HIV Studies: In April 2008, the Company began animal studies against HIV in a mouse model. Subsequent reports in May 2008 indicated significant therapeutic efficacy.
- Ebola and Rabies: Cell culture studies against Ebola showed high efficacy. Previous animal studies for Rabies showed 20-30% survival rates in lethally infected mice, compared to 0% for standard care.
- Government Agreements: The Company has Cooperative Research and Development Agreements (CRADAs) with the Walter Reed Army Institute of Research (Dengue Fever), USAMRIID (Filovirus/Ebola), and the Armed Forces Institute of Pathology (H5N1/HIV).
Risks and Contingencies
- Going Concern: Significant operating losses and capital requirements raise substantial doubt about the ability to continue operations without further financing.
- Licensing Dependency: The Company relies entirely on a license from TheraCour Pharma, Inc. (a related party). While TheraCour has granted permissive use for additional viruses (Dengue, Ebola, EKC), no written amendment has been finalized. Failure to secure this amendment could terminate government CRADAs.
- Internal Controls: Management concluded that disclosure controls were not effective as of March 31, 2008, due to the departure of the CFO and inherent weaknesses in financial statement preparation.
Investor Verification Checklist
- Runway Validation: Verify if the Company has secured the estimated $2.5 million to $5 million in additional financing required to operate beyond August 2008.
- Licensing Status: Confirm the status of the written amendment with TheraCour Pharma, Inc. regarding rights to Dengue, Ebola, and EKC viruses, as this is critical for ongoing government contracts.
- Related Party Transactions: Review the terms of the license agreement and development fees paid to TheraCour Pharma, Inc., which is controlled by the Company's President and owns ~30% of the Company.
- Internal Controls: Assess the progress of remediation efforts regarding the ineffective disclosure controls and the search for a permanent CFO.
- Regulatory Path: Monitor the timeline and results of the HIV animal studies and the subsequent plan to file an Investigational New Drug (IND) application with the FDA.